Nintedanib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 100 mg, 150 mg
Reference Brands: Ofev (USA, EU), Vargatef (EU)
Category:
Oncology Cancer Care
Nintedanib is available in Capsules
and strengths such as 100 mg, 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Nintedanib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Nintedanib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Nintedanib is an oral medication prescribed for the treatment of idiopathic pulmonary fibrosis (IPF) and certain types of non-small-cell lung cancer (NSCLC) when used in combination with other therapies. It belongs to the class of small-molecule tyrosine kinase inhibitors and works by targeting multiple growth factor receptors, including VEGFR, FGFR, and PDGFR. By inhibiting these pathways, nintedanib reduces fibroblast proliferation, slows ongoing fibrotic processes, and delays progression of irreversible tissue damage.
Sold under the brand names Ofev and Vargatef, nintedanib is available in oral capsule formulations, typically 100 mg and 150 mg. It is also indicated for systemic sclerosis-associated interstitial lung disease and progressive fibrosing interstitial lung disease, making it a critical therapy for patients with progressive fibrotic conditions.
Nintedanib therapy requires careful patient monitoring due to potential adverse effects, including liver enzyme elevations and gastrointestinal issues. Its pharmacokinetic profile allows for targeted, individualized treatment, and understanding drug interactions is essential to optimize efficacy and safety. Nintedanib provides clinicians with an effective option to manage fibrotic lung diseases and certain cancers, supporting improved patient outcomes and delaying disease progression.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing